Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthAetna Tourette's Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0480

    Tourette's Syndrome

    Customize your policy alerts

    Sign up for Aetna Policy 0480 alerts

    Get alerted when Policy 0480 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing medical necessity, covered assessments, and treatments for Tourette's syndrome for Aetna members; applies to clinical providers seeking coverage determination for diagnostic and therapeutic services.

    Policy Summary
    PayerAetna
    PolicyTourette's Syndrome
    Policy CodePolicy 0480
    Change TypeNo material change
    Effective DateJul 3, 2001
    Last ReviewFeb 16, 2024
    Next Review DateMay 9, 2024
    Key ActionDocument prior trials of pharmacologic and behavioral therapies and evidence of significant functional impairment when requesting coverage for advanced interventions such as deep brain stimulation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    F95.2ICD-10 code specified for Tourette's disorder
    9+pharmacotherapies listed as medically necessary options
    27procedures/services listed as experimental/investigational
    mixedDBS outcomes
    supportedHRT/CBIT evidence

    Coverage Criteria

    inv-01: Medical necessity — diagnostic selection criteria

    Covered when ALL of the following are met:

    Diagnosis criteria for Tourette's syndrome: 1) Both multiple motor and 1 or more vocal tics have been present at some time during the illness; 2) The disturbance causes significant distress or marked impairment in social, occupational, or other important areas of functioning; 3) The disturbance is not due to direct physiological effects of a substance or general medical condition; 4) Onset before age 21 years; 5) Tics occur many times a day (usually in bouts) almost every day or periodically for >1 year with no tic-free period >3 consecutive months.

    All five elements must be met.

    inv-02: Covered assessments and treatments

    When the above selection criteria are met, the following are considered medically necessary:

    Assessment services: Electroencephalography (EEG) or neurology consult (only in the presence of focal signs or clinical suggestion of seizure/degenerative condition); medical evaluation including complete history and physical examination.
    Policy Summary
    PayerAetna
    PolicyTourette's Syndrome
    Policy CodePolicy 0480
    Change TypeNo material change
    Effective DateJul 3, 2001
    Last ReviewFeb 16, 2024
    Next Review DateMay 9, 2024
    Key ActionDocument prior trials of pharmacologic and behavioral therapies and evidence of significant functional impairment when requesting coverage for advanced interventions such as deep brain stimulation.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and Prior AuthorizationBackgroundDefinitionsLevel of Care CriteriaTreatment ModalitiesVisit Limits and Utilization

    EEG/neurology consult is conditional and indicated only with focal signs or suspicion of seizure/degenerative disease.

    Treatment services: Pharmacotherapies (aripiprazole; clonazepam; clonidine; fluphenazine; haloperidol; pimozide; risperidone; tetrabenazine; tricyclic antidepressants for comorbid ADHD) and psychotherapy when member exhibits anxiety and/or depression.

    Self‑administered medications are covered under the pharmacy benefit; formulary restrictions may apply.

    inv-03: DBS — candidate selection

    Covered when ALL of the following are met (per guideline consensus and study contexts):

    DBS candidate criteria: 1) Patient is an adult with severe Tourette's syndrome causing significant functional impairment; 2) Symptoms are refractory to conventional pharmacologic and behavioral treatments (documented trials of appropriate medications and behavioral therapy); 3) Treatment is provided within a controlled trial or multidisciplinary program with specialized evaluation and follow-up; 4) Risks and potential cognitive/oculomotor adverse effects and device-related risks have been discussed and documented.

    Based on European guideline recommendations and published DBS studies; DBS should be performed in specialized centers and ideally within controlled trials.

    inv-04: Pharmacologic and behavioral therapy — Initial and continued therapy

    Initial and continued therapy — consider medications and behavioral therapy as first-line:

    First-line/established treatments: Use of alpha‑2 agonists (clonidine, guanfacine), especially in children; antipsychotics (e.g., haloperidol, pimozide, fluphenazine, risperidone, aripiprazole and others) and tetrabenazine may reduce tics; habit reversal training / CBIT is an evidence‑based behavioral option; selection should balance efficacy and adverse‑effect profile.

    Recommendations derived from systematic reviews and guideline consensus; stronger preference for alpha‑2 agonists in children.

    inv-05: Experimental or insufficient evidence treatments

    Not routinely covered/considered experimental or investigational when used for TS outside trials:

    Experimental/insufficient evidence: Botox (botulinum toxin) injections, biofeedback (EEG/neurofeedback outside validated protocols), bilateral stereotactic anterior cingulate lesions, bilateral thalamic stimulation in non‑DBS contexts, intravenous immunoglobulins (IVIG), repetitive transcranial magnetic stimulation (rTMS), cannabinoids, and some novel anti‑glutamatergic agents and new VMAT2 inhibitors lack sufficient evidence and should be considered investigational outside of controlled studies.

    Cochrane and systematic reviews cite insufficient or preliminary evidence for these interventions.

    inv-06: Evidence-based treatment considerations

    Clinical guidance and evidence summaries indicating when therapies may be appropriate:

    First-line pharmacologic (children): Alpha‑2 adrenergic receptor agonists (clonidine, guanfacine) are favored as first‑line agents for children with tics.

    Based on systematic reviews and guideline consensus.

    Second-line pharmacologic: Antipsychotics may be useful for tic reduction but carry higher risk of adverse effects and are generally reserved for when alpha‑2 agonists are ineffective or not tolerated.

    Weak recommendations due to side‑effect profiles.

    Behavioral therapy: Habit reversal training/Comprehensive Behavioral Intervention for Tics (HRT/CBIT) is supported as effective and is an option for patients preferring nonpharmacologic care or who have not tolerated medications.

    CBIT evidence graded as probably efficacious/moderate confidence in systematic reviews.

    Botulinum toxin injections may be considered for focal motor or vocal tics, but randomized evidence is very limited and effects are uncertain.

    Evidence limited to small trials and case series.

    Deep Brain Stimulation (DBS): DBS may be an option for a subset of medically refractory, severely disabled patients; randomized trials (aGPi DBS) did not show significant short‑term benefit and reported serious adverse events; optimal targets and long‑term benefit remain uncertain.

    DBS considered evolving; careful patient selection and multidisciplinary evaluation required.

    Pharmacologic agents noted in guidance: Tetrabenazine and classical antipsychotics have shown substantial tic reduction in some patients; tetrabenazine may be useful as an alternative to typical neuroleptics but has its own adverse effects (depression, parkinsonism).

    Guideline and review sources describe efficacy and adverse‑effect considerations.

    inv-07: Evidence summaries for investigational/early treatments

    Evidence summaries and outcomes for investigational treatments in this document section

    Neurosurgical and neuromodulation approaches (pilot/early trials): Prefrontal cortical electrical stimulation (pilot N=4) showed tic improvement at 6 months with tendency to re‑emerge at 12 months; findings are proof‑of‑concept and need validation in larger well‑designed studies.

    Pilot study data; clinical significance unconfirmed.

    Noninvasive neurostimulation (CES): Cranial electrotherapy stimulation (randomized sham‑controlled trial N=62) showed tic improvements in both active and sham groups without significant between‑group difference at 4 weeks; authors noted possible placebo effect and recommended larger trials.

    No definitive superiority over sham demonstrated.

    Neurofeedback: Real‑time fMRI neurofeedback from the SMA in a randomized, double‑blind, sham‑controlled crossover trial (N=21 adolescents) produced a clinically meaningful greater reduction in YGTSS after real neurofeedback versus sham (effect size ~0.59), but mechanisms remain unclear and replication is needed.

    Early randomized evidence in small sample.

    Behavioral therapies (relaxation): Relaxation therapy in small controlled trials (total N=40) decreased tic severity but was less effective than habit reversal in at least one trial; overall evidence limited by small sample sizes and heterogeneity.

    Preliminary behavioral data.

    Pharmacologic: ecopipam: Phase IIb randomized trial in children/adolescents (~153 randomized) showed statistically significant reduction in YGTSS‑TTS at 12 weeks versus placebo; phase III evaluation planned to assess durability.

    Promising phase IIb data pending larger confirmatory trials.

    Pharmacologic: deutetrabenazine: Multiple randomized trials (phase II/III and phase III ARTISTS 2) in children/adolescents failed to meet primary efficacy endpoints versus placebo, indicating lack of demonstrated benefit in these studies.

    Negative/inconclusive RCT results reported.

    Biomarkers: immune markers and microRNAs: Meta‑analysis and narrative reviews report altered cytokines/T‑cell subsets and exploratory microRNA findings in TS, but clinical utility as biomarkers is not established.

    Biomarker research remains investigational and not ready for clinical application.

    Numerous assessment and treatment procedures are explicitly listed as experimental and investigational for Tourette's syndrome due to insufficient evidence of effectiveness. Examples include advanced assessments (e.g., computerized EEG/brain mapping, measurement of cytokines or T‑cell subsets, microRNAs as biomarkers, routine neuroimaging for diagnosis) and a broad range of therapeutic interventions (e.g., adaptive/responsive deep brain stimulation, several neuromodulation techniques, IVIG, many novel pharmacologic agents, and behavioral/device combinations). These services are identified in the policy as not supported for routine clinical use outside of well‑designed clinical trials.

    Most Aetna medical plans exclude coverage of educational interventions. Under these plans, educational and achievement testing and educational interventions (including classroom environmental manipulation, academic skills training, and parental training) are not covered; providers and members should check the member's benefit plan description for specific coverage details.

    The policy specifically lists several examples of procedures and treatments considered investigational or lacking sufficient evidence for Tourette's syndrome, including botulinum toxin (Botox) injections, various forms of biofeedback/EEG neurofeedback, bilateral stereotactic lesions of the anterior cingulate gyrus, bilateral thalamic stimulation (outside established DBS contexts), intravenous immunoglobulins (IVIG), and repetitive transcranial magnetic stimulation (rTMS). These interventions are not routinely covered for TS outside controlled clinical studies.

    A systematic review and meta-analysis found limited and mixed data regarding the use of sodium valproate in children with Tourette's syndrome. While some small randomized trials reported reductions in YGTSS scores versus controls, pooled analyses showed no significant difference for number of tics in several trials; the authors concluded that routine use of sodium valproate in children with TS is not recommended based on the limited evidence and that further well‑conducted long‑term trials are needed.

    Evidence for cannabinoid-based products in Tourette's is limited. A Cochrane review identified only two small randomized trials (total n=28) of delta‑9‑THC with modest and inconsistent improvements on some measures; larger reviews of cannabinoid RCTs across psychiatric disorders found limited short‑term effects and no evidence supporting mid‑ to long‑term effectiveness. Accordingly, cannabinoid products and cannabis flower are considered investigational for TS pending more robust data.

    Randomized clinical trials of deutetrabenazine in children and adolescents with Tourette's syndrome did not demonstrate statistically significant improvement versus placebo on primary YGTSS endpoints in multiple phase II/III and phase III studies (including ARTISTS‑2). Trial results therefore do not support routine coverage of deutetrabenazine for tic reduction outside of research contexts, and any consideration should document trial details and the lack of demonstrated efficacy.

    This Clinical Policy Bulletin provides a general description of plan or program benefits and criteria for Tourette's syndrome assessment and treatment. It is not a contract and does not replace the member's benefit plan documents; coverage determinations remain subject to the specific terms, exclusions, and limitations of the member's health plan.

    Procedures and services listed under the policy's Experimental and Investigational section are considered not medically necessary for Tourette's syndrome due to insufficient evidence for this indication. Examples include adaptive DBS variants, cannabinoids, cranial electrotherapy stimulation, EEG biofeedback, IVIG, many novel neuromodulation techniques, deutetrabenazine, valbenazine, tDCS, rTMS variants, and others listed in the policy.

    Cochrane and systematic reviews identified only small randomized trials of cannabinoids for tics (combined n approximately 28 across trials) and concluded there is insufficient evidence to support their use for tics or obsessive‑compulsive symptoms in TS; broader reviews similarly reported low‑to‑moderate quality evidence and no support for cannabis flower or current cannabinoid products as effective mid‑ or long‑term treatments.

    Several interventions have low‑quality or insufficient evidence and are therefore considered investigational or not medically necessary for TS pending larger, rigorous trials. Examples include N‑acetylcysteine (NAC) (randomized trial showed no benefit), acupuncture (small trials with bias concerns), and various dietary or other physical interventions where evidence is limited or of low certainty.

    Available trials of cannabis flower and related cannabinoid products do not provide robust evidence of benefit for Tourette's syndrome, and systematic reviews have highlighted trial limitations, small sample sizes, and failure to demonstrate durable effects. The policy therefore does not support use of cannabis flower or current cannabinoid formulations for TS outside investigational settings.

    Many neuromodulation and device approaches remain in early, small, or single‑site pilot studies without replication. Examples include prefrontal cortical electrical stimulation (pilot N=4 with transient benefit at 6 months), cranial electrotherapy stimulation (CES) (randomized sham‑controlled trial with no significant between‑group difference at 4 weeks), and real‑time fMRI neurofeedback (small randomized crossover trial showing promise but requiring validation). These interventions are investigational until larger confirmatory studies are available.

    Coding

    Covered CPT/HCPCS codes if selection criteria are metmixedCovered
    90785Interactive complexity (List separately in addition to the code for primary procedure).
    90832Psychotherapy, 30 minutes with patient and/or family member.
    90838Psychotherapy, 60 minutes with patient and/or family member when performed with an evaluation and management service (List separately in addition to the code for primary procedure).
    90839Psychotherapy for crisis; first 60 minutes.
    90840Psychotherapy for crisis; each additional 30 minutes (List separately in addition to code for primary service).
    95812-95830Routine electroencephalography.
    99201-99215Evaluation and management, office or other outpatient services.
    0042TCerebral perfusion analysis using computed tomography with contrast administration, including post-processing of parametric maps with determination of cerebral blood flow, cerebral blood volume, and mean transit time.
    61735Creation of lesion by stereotactic method; subcortical structure(s) other than globus pallidus or thalamus.
    61863-61868Stereotactic implantation of neurostimulator electrode array in subcortical site, with/without microelectrode recording (includes related 61864, 61867, 61868).
    1–10 of 41
    1/5
    HCPCS and DME codes listed (some noted as not covered for indications)mixed
    E0732Cranial electrotherapy stimulation (CES) system, any type.
    A4596Cranial electrotherapy stimulation (CES) system supplies and accessories, per month.
    A9583Injection, Gadofosveset Trisodium, 1 ml.
    A9585Injection, gadobutrol, 0.1 ml.
    L8679-L8689Implantable neurostimulator and related device codes (generators, programmers, adaptors, recharging systems).
    ICD-10 codesICD-10Covered
    F95.2Tourette's disorder
    Drug and infusion-related codes referencedmixed
    J1561-J1569Various immune globulin IV/IM product codes (e.g., Gamunex, Octagam, Gammagard), 500 mg units.
    J0132Injection, acetylcysteine, 100 mg.
    J0475-J0476Baclofen injections / intrathecal trial codes (10 mg and intrathecal trial 50 mcg).
    J0585-J0587Botulinum toxin type A/B codes (per unit/100 units).
    Duration of tics for diagnosis — inv-24
    Required duration> 1 year with no tic-free period > 3 consecutive months
    Frequency during diagnostic periodTics occur many times a day (usually in bouts) almost every day or periodically throughout the >1 year period
    Concurrent tic typesBoth multiple motor and one or more vocal tics must have been present at some time during the illness
    Age of onsetOnset before the age of 21 years required for diagnosis

    Provider Actions and Prior Authorization

    Prior Authorization

    Coverage contingent on meeting Tourette's selection criteria

    Certain procedure and drug codes listed in this policy are covered only when the Tourette’s selection criteria are met; prior authorization may be required per plan for these services.

    • Covered CPT/HCPCS examples include psychotherapy (90832, 90838), EEG (95812–95830), evaluation/management (99201–99215), and device/implantation codes (61863–61868, 95970–95984).
    • Self‑administered medications are covered under the pharmacy benefit; formulary restrictions may apply.
    Prior Authorization

    Prior authorization: deep brain stimulation (DBS) requires documentation

    DBS should be considered only for adult patients with severe, treatment‑refractory Tourette’s syndrome and ideally performed within controlled trials or specialized multidisciplinary programs; prior authorization should require documentation of prior therapies tried and functional impairment.

    • Candidate selection per ESSTS: adult, treatment‑resistant, severely affected patients; recommend DBS be performed in context of controlled trials.
    • Prior authorization should verify documented trials of appropriate medications and behavioral therapy and evidence of significant functional impairment.
    Prior Authorization

    DBS for refractory TS: evolving option with safety considerations

    DBS is an evolving option for a subset of medication‑refractory, severely affected patients and is associated with serious adverse events; prior authorization should verify medical refractoriness, prior therapies attempted, and that informed consent about risks was obtained.

    • Registry and reviews note symptomatic improvement but also important adverse events and device complications.
    • Randomized/controlled DBS trials reported serious adverse events (infections, electrode misplacement) and inconclusive short‑term efficacy.
    Prior Authorization

    Prior authorization: neurosurgical/implant procedures often investigational

    Procedures such as deep brain stimulation variants (including combined DBS/capsulotomy) and cortical electrical stimulation are described as investigational or preliminary and would typically require prior authorization with supporting documentation of treatment‑refractoriness and multidisciplinary evaluation.

    • Preliminary neurosurgical approaches (e.g., GPi‑DBS with capsulotomy) are reported only in small series and need validation by well‑designed studies.
    • Prefrontal cortical electrical stimulation is a pilot proof‑of‑concept intervention requiring confirmatory trials.
    Prior Authorization

    Prior authorization: investigational/off‑label pharmacotherapies need trial evidence

    Consider prior authorization for investigational or off‑label pharmacologic agents when evidence is limited; include trial‑grade evidence and patient‑specific rationale in the request to support medical necessity.

    • Document trial phase, baseline YGTSS scores, age range, and treatment duration for investigational agents (e.g., ecopipam, deutetrabenazine).
    • Drugs with negative or inconclusive RCT results (e.g., deutetrabenazine) may not meet coverage criteria without compelling justification.
    Note

    Administrative note: no specific prior‑auth procedures defined in this policy text

    The policy text does not specify additional administrative prior‑authorization rules beyond the clinical guidance; check plan‑specific prior authorization procedures.

    • Administrative/prior‑auth procedures and contact details are provided elsewhere in plan materials; this policy describes clinical criteria rather than plan administrative workflows.
    Billing Rule

    Pharmacotherapy coverage and formulary considerations

    Pharmacotherapy options enumerated include typical antipsychotics, risperidone, clonidine, clonazepam, tetrabenazine, and tricyclic antidepressants; self‑administered meds are covered under the pharmacy benefit and may be subject to formulary restrictions.

    • Examples listed as medically necessary when selection criteria met: aripiprazole, clonazepam, clonidine, fluphenazine, haloperidol, pimozide, risperidone, tetrabenazine, tricyclics.
    • Check pharmacy formulary for coverage and prior‑authorization requirements.
    Step Therapy

    Stepwise treatment: trial established medications and behavioral therapy first

    Use established pharmacotherapies (alpha‑2 agonists, dopamine‑blocking agents, VMAT2 inhibitors) and behavioral therapy before considering invasive or experimental interventions; document prior trials and responses.

    • Canadian guidelines and reviews recommend clonidine/guanfacine (strong for children) and antipsychotics or tetrabenazine where indicated.
    • Prior authorization for advanced interventions should confirm failure/intolerance of appropriate pharmacologic and behavioral therapies.
    Step Therapy

    Pediatric step preference: start with alpha‑2 agonists

    For pediatric pharmacologic treatment, alpha‑2 adrenergic agonists (clonidine, guanfacine) are favored as first‑line agents; reserve antipsychotics for when these are ineffective or poorly tolerated.

    • Systematic reviews show moderate certainty for clonidine/guanfacine benefit in children.
    • High side‑effect rates with antipsychotics lead to weaker recommendations—use when benefits outweigh risks.
    Step Therapy

    Pharmacologic step considerations: mixed evidence for VMAT2 and novel agents

    Evidence for VMAT2 inhibitors and other novel agents is mixed or insufficient; document prior trial history and rationale when seeking coverage for these agents.

    • Open‑label and small trials have mixed results (valbenazine failed to show statistical efficacy; deutetrabenazine trials failed primary endpoints).
    • Provide prior treatment history and justification if requesting coverage for VMAT2 or other novel agents.
    Step Therapy

    Behavioral therapy (CBIT/HRT) recommended as initial step

    Behavioral interventions such as Comprehensive Behavioral Intervention for Tics (CBIT)/habit reversal therapy and relaxation techniques have evidence of effectiveness and should be considered early as initial therapy.

    • Systematic reviews show HRT/CBIT reduces tics with moderate certainty; relaxation therapy showed benefit in small trials but less than HRT.
    • Document trials of behavioral therapy (CBIT/HRT) when considering escalation to pharmacologic or invasive therapies.
    Note

    No explicit administrative step‑therapy rules defined in this policy

    No formal step‑therapy rules (programmatic forced‑step requirements) are defined in the reference and policy history chunks; clinical guidance emphasizes trial of established behavioral and pharmacologic options prior to investigational or surgical therapies.

    • Policy provides clinical sequencing guidance but does not prescribe explicit administrative step‑therapy pathways or visit limits.
    • Check plan specifics for any operational step‑therapy programs.
    Documentation Required

    Required clinical documentation for diagnosis

    Medical evaluation including complete history and physical examination is necessary for diagnosis; EEG or neurology consult is indicated only with focal signs or clinical suggestion of seizure or degenerative condition.

    • Diagnosis is clinical—document history, family history, direct observation, and physical exam.
    • Order EEG/neurology consult only when focal signs or seizure are suspected.
    Documentation Required

    Clinical justification required for advanced/surgical therapies

    Clinical justification for advanced or surgical therapies must document significant functional impairment, failure of conventional pharmacologic and behavioral interventions, and rationale for target selection given variable evidence across targets.

    • Documentation should include trials attempted, objective measures of tic severity/functional impact, and multidisciplinary evaluation.
    • Discuss risks (cognitive, oculomotor adverse effects) and obtain informed consent.
    Documentation Required

    DBS candidate documentation: severity, refractoriness, prior therapies, and outcome measures

    For DBS candidate consideration, include documentation of severe, medically refractory Tourette’s syndrome, prior treatments tried and failed, target selection rationale, and anticipated benefit; reported trials enrolled adults 18–60 with severe refractory TS.

    • Include pre‑ and post‑procedure standardized tic severity scores (e.g., YGTSS, Modified Rush) used in trials.
    • Confirm multidisciplinary assessment and that DBS is being considered in a specialized program or trial.
    Documentation Required

    Documentation: include severity, prior therapy history, target rationale, and standardized outcome measures

    Required documentation for advanced interventions should include severity and refractoriness of tics, prior therapy history, target selection rationale, and pre‑ and post‑procedure standardized tic severity scores (e.g., YGTSS, Modified Rush).

    • Trials and reports routinely use YGTSS and Modified Rush scores—include baseline and follow‑up values.
    • For investigational devices or combined procedures, provide trial phase or registry identifiers when applicable.
    Documentation Required

    Document trial details when requesting coverage for investigational therapies

    When considering investigational therapies in a trial context (e.g., ecopipam, deutetrabenazine), document trial phase, patient age range, baseline YGTSS scores, treatment duration, and other trial parameters to support prior authorization or coverage decisions.

    • Phase IIb ecopipam trial enrolled children/adolescents with baseline YGTSS‑TTS ≥20 and reported significant reduction at 12 weeks.
    • Deutetrabenazine phase II/III and ARTISTS 2 trials failed to meet primary endpoints—include trial results when requesting coverage.
    Note

    Administrative resources and contact information — follow plan procedures

    Administrative resources, policy glossary, and contact information are provided in the policy materials, but no additional provider‑level documentation requirements are specified in these reference chunks.

    • Policy history and additional information links are available; follow plan‑specific administrative instructions for prior authorization submission and contacts.
    Denial Risk

    Denial risk: experimental and investigational interventions

    Requests for procedures and services listed as experimental and investigational (e.g., DBS variants, cannabinoids, cranial electrotherapy stimulation, EEG biofeedback, IVIG, and many novel pharmacologic or neuromodulation techniques) are considered experimental/investigational and can be denied.

    • The policy explicitly lists numerous assessment and treatment procedures as experimental/investigational and not routinely covered outside controlled studies.
    • Prior authorization requests lacking sufficient evidence or trial context for these interventions may be denied.
    Denial Risk

    Denial risk: inadequate documentation for DBS candidate selection

    DBS is recommended only for adult, treatment‑resistant, severely affected patients and ideally performed in the context of controlled trials; lack of documentation of treatment resistance or inadequate prior‑therapy evidence may trigger denial.

    • ESSTS guidance strongly recommends DBS only in adults with severe, treatment‑resistant TS and within controlled trials.
    • Prior authorization should document failed adequate trials of pharmacologic and behavioral therapies and functional impairment.
    Denial Risk

    Denial risk: DBS short‑term efficacy and safety concerns

    A randomized short‑term trial of aGPi DBS showed no significant difference in tic severity during the 3‑month blinded period and reported serious adverse events (including infections and device complications); absence of demonstrated short‑term benefit or inadequate safety discussion may lead to denial.

    • Welter et al (aGPi DBS) found no significant YGTSS improvement at 3 months and reported 15 SAEs including infections and electrode misplacement.
    • Prior authorization should include discussion of SAEs and rationale for proceeding despite mixed short‑term trial results.
    Denial Risk

    Denial risk: preliminary evidence for combined neurosurgical/neurostimulation approaches

    Interventions such as GPi‑DBS combined with anterior capsulotomy and prefrontal cortical electrical stimulation are preliminary and based on small or uncontrolled series; lack of well‑designed studies may lead to noncoverage or denial if considered experimental.

    • GPi‑DBS combined with capsulotomy reported favorable outcomes in a small retrospective series but requires validation by well‑designed studies.
    • Pilot prefrontal cortical stimulation studies (N=4) showed transient improvement and need confirmatory trials.
    Denial Risk

    Denial risk: negative or inconclusive RCT evidence may affect drug coverage

    Drugs with negative or inconclusive randomized controlled trial results (for example, deutetrabenazine trials that failed to meet primary endpoints) may not meet criteria for coverage as effective treatments without additional supporting evidence.

    • ARTISTS 2 and other deutetrabenazine studies did not demonstrate significant benefit versus placebo in primary endpoints.
    • Prior authorization requests for such agents should include compelling patient‑specific rationale and trial data if seeking coverage.
    Note

    Note: references and policy history do not define authorization/denial rules

    The policy reference and history chunks do not present explicit authorization or denial criteria; they provide bibliographic references, policy history, and administrative notes only.

    • Administrative policy history and references are available in the policy materials but do not substitute for plan prior‑authorization rules.
    • For coverage decisions, apply the clinical criteria and investigational/exclusion lists in this policy and follow plan procedures.

    Background

    Tourette's syndrome is a familial neurobehavioral disorder characterized by fluctuating motor and vocal tics that typically begin in childhood or adolescence. Diagnosis is clinical and requires multiple motor tics and one or more vocal tics at some time, onset before age 21, and persistence of tics many times per day for more than 1 year with no tic‑free period greater than 3 consecutive months. There are no definitive laboratory tests; a medical history, physical examination, and direct observation are required, and EEG or neurology consultation is reserved for cases with focal signs or concern for seizure or other neurologic disease.

    Definitions

    Motor and vocal tics — inv-50
    Motor tics — simple examplesEye blinking, neck jerking, shoulder shrugging, facial grimacing
    Motor tics — complex examplesFacial gestures, hitting or biting oneself, jumping, touching, stamping, smelling
    Vocal tics — simple examplesCoughing, throat clearing, grunting, sniffing, snoring, barking
    Vocal tics — complex examplesPalilalia, echolalia, coprolalia, repeating words or phrases out of context
    Diagnostic selection criteria for Tourette's syndrome — inv-51
    Core requirementBoth multiple motor and one or more vocal tics present at some time during the illness
    Functional impactDisturbance causes significant distress or marked impairment in social, occupational, or other important areas of functioning
    Exclusion for other causesDisturbance not due to direct physiological effects of a substance or a general medical condition
    Age and durationOnset before age 21; tics present many times a day over >1 year with no tic-free period >3 consecutive months
    TS-related metabolic pattern (TSRP) — inv-52
    Imaging modalityIdentified using [18F]-fluorodeoxyglucose positron emission tomography (FDG‑PET)
    Pattern descriptionReduced resting metabolic activity of the striatum and orbitofrontal cortex with relative increases in premotor cortex and cerebellum
    Distinguishing rolePattern (TSRP) completely separated TS patients from controls in the cited study (p < 0.0001)
    OCD-related pattern (OCDRP) — inv-53
    Imaging modalityDerived from FDG‑PET spatial covariance analysis within TS patients
    Pattern descriptionReduced activity of anterior cingulate and dorsolateral prefrontal cortex with relative increases in primary motor cortex and precuneus
    Clinical correlationExpression of this OCD-related pattern (OCDRP) correlated with OCD severity (r = 0.79, p < 0.005) within TS cohort
    Habit reversal therapy (HRT) — inv-54
    Core componentsAwareness training, relaxation training, competing response training, and contingency management
    Therapeutic goalTrain patient to detect premonitory urges and use a competing muscular response incompatible with the tic
    Protocol variabilityInvestigators/clinicians may vary protocols, but competing response is a core feature
    Tetrabenazine (TBZ) — inv-55
    Mechanism classVesicular monoamine transporter type 2 (VMAT2) inhibitor
    Pharmacologic actionDepletes central dopamine and is used for hyperkinetic movement disorders; reduces tic frequency/intensity
    Clinical use noteSuggested as a treatment option for bothersome tics; starting dose examples cited (e.g., 12.5 mg daily) in guidance
    HRT/CBIT — inv-56
    DefinitionBehavioral therapy including habit reversal training and broader CBIT approaches to reduce tics
    Components and deliveryTypically delivered as awareness training, competing response practice, relaxation, and contingency management; offered when patients prefer nonpharmacologic care or have not tolerated meds
    Evidence noteClassified as probably efficacious/moderately supported by systematic reviews and guideline statements
    Adaptive (responsive) DBS — inv-57
    System typeClosed-loop (adaptive/responsive) deep brain stimulation
    Control signalUses neurophysiologic biomarkers such as local field potentials (LFPs) recorded from implanted electrodes to adjust stimulation in real time
    Intended benefitsAims to optimize clinical benefit, limit side effects, and reduce battery depletion compared with continuous DBS
    Theta burst stimulation (TBS) — inv-58
    Stimulation patternPatterned form of rTMS delivering bursts of 3 pulses at 30–50 Hz repeated at 5 Hz
    Delivery modesCan be delivered as continuous TBS (cTBS) or intermittent TBS (iTBS)
    Application noteUsed as a noninvasive brain stimulation approach targeting regions such as the supplementary motor area in TS studies
    YGTSS — inv-59
    DefinitionYale Global Tic Severity Scale (YGTSS) — standardized clinician-rated instrument to quantify tic severity
    Role in trialsPrimary outcome measure used across many TS clinical trials to assess treatment effect on tics
    Use in documentationRecommended for pre- and post-intervention standardized tic severity assessment (e.g., DBS and pharmacologic trials)
    Ecopipam — inv-60
    Pharmacologic classSelective dopamine D1 receptor antagonist
    Study population/contextStudied in randomized, double-blind, placebo-controlled trials in children and adolescents with moderate-to-severe TS (phase IIb cited)
    Efficacy/safety notePhase IIb trial showed statistically significant reduction in YGTSS-TTS at 12 weeks versus placebo with tolerable adverse effects
    Policy history / Definitions link — inv-61
    Policy reviewsLast review: 02/16/2024; Next review: 05/09/2024; Effective date: 07/03/2001
    Definitions resourcePolicy includes a link to a Definitions page for additional term clarifications
    Reference materialsPolicy history and review history are provided for context and updates

    Level of Care Criteria

    Treatment Modalities

    inv-67: Pharmacotherapy and Psychotherapy

    Pharmacotherapy: Use of listed medications (typical antipsychotics, risperidone, clonidine, clonazepam, tetrabenazine, tricyclics) when diagnostic criteria are met and symptoms impair functioning.

    Self‑administered medications covered under pharmacy benefit; formulary restrictions may apply.

    Psychotherapy indicated when member has comorbid anxiety or depression; behavioral therapies (HRT/CBIT) supported as effective for tic reduction.

    Covered under behavioral health benefits; continuation guided by clinical response.

    inv-68: Habit Reversal Therapy (HRT)

    HRT criteria: HRT includes awareness training, relaxation, competing response training, and contingency management; considered probably efficacious though studies have methodological limitations.

    Behavioral protocol components as described in HRT literature.

    inv-69: Deep Brain Stimulation (DBS)

    DBS modality criteria: DBS considered for adults with severe, treatment‑refractory TS; target selection varies (thalamus, GPi, nucleus accumbens); evidence is preliminary; informed consent and multidisciplinary evaluation required.

    Selection and target uncertainty noted across case series and reviews.

    inv-70: Behavioral therapy (HRT/CBIT, mindfulness-based approaches)

    Behavioral therapy (HRT/CBIT, mindfulness): Behavioral therapy (HRT/CBIT) is effective (Grade/moderate evidence) and suggested for patients preferring nonpharmacologic care or who have not tolerated medications; mindfulness‑based approaches (MBSR) show preliminary positive results in small uncontrolled trials.

    Evidence from systematic reviews and pilot studies supports behavioral approaches.

    inv-71: Deep brain stimulation (DBS)

    DBS selection: Candidate selection for DBS should include severe disability, documented failure of medical and behavioral therapies, multidisciplinary evaluation, and informed consent acknowledging uncertain benefit and risk of serious adverse events.

    Randomized trial data show mixed results and notable serious adverse events; long‑term outcomes and optimal targets remain uncertain.

    inv-72: DBS, responsive DBS, capsulotomy, cortical stimulation, tDCS, rTMS/TBS

    Advanced neuromodulation and surgical modalities: Includes thalamic DBS, GPi‑DBS, nucleus accumbens targets, adaptive/responsive DBS (LFP‑based), combined GPi‑DBS with capsulotomy, prefrontal cortical electrical stimulation, and noninvasive methods (tDCS, rTMS, TBS); evidence ranges from case reports and small pilots to limited RCT data and remains preliminary.

    Many modalities are experimental or evolving; careful evaluation required.

    inv-73: Neurofeedback

    Neurofeedback: Real‑time fMRI neurofeedback from the supplementary motor area produced clinically meaningful tic reduction in a small randomized crossover trial (N=21 adolescents), but replication is needed before routine clinical use.

    Considered investigational until validated in larger studies.

    inv-74: Various (pharmacologic, behavioral, surgical, neuromodulation)

    Various treatment modalities summary: Multiple pharmacologic agents, behavioral interventions, neuromodulation and surgical approaches have been studied for Tourette's syndrome; evidence quality and outcomes vary widely across modalities and trials—some show benefit (e.g., alpha‑2 agonists, antipsychotics, CBIT) while others remain investigational or have inconclusive RCT results (e.g., deutetrabenazine, many neuromodulation techniques).

    Review and RCT references summarized in policy references.

    Visit Limits and Utilization

    No explicit visit limits provided — inv-75
    Visit limits statementNo explicit visit limits provided in this excerpt; psychotherapy CPT codes are listed as covered when selection criteria are met
    Representative psychotherapy codesExamples include CPT 90832, 90838, 90839, 90840 listed as covered when criteria are met
    Benefit notePsychotherapeutic interventions are covered under the member's behavioral health benefits; check plan benefit descriptions for details